The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed,...read more
Nuvalent, a preclinical oncology biotech developing small molecule kinase inhibitors, raised $166 million by offering 9.8 million shares at $17, within the range of $16 to $18. The company offered 0.9 million more shares than anticipated. Nuvalent focuses on...read more
Nuvalent, a preclinical oncology biotech developing small molecule kinase inhibitors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $151 million by offering 8.9 million shares at a price range of $16 to $18. At the...read more
After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million. Preclinical RNA biotech Transcode Therapeutics (RNAZ) priced at $4 to...read more
US IPO Weekly Recap: Biotechs pop and Robinhood flops in a record 20 IPO week
The 2021 US IPO market continues to break records. 20 IPOs went public this past week, the most in a single week since the year 2000. New filers have slowed ahead of the August lull, with just one IPO submitting an initial filing. Three issuers postponed,...read more
Oncology biotech Nuvalent prices upsized IPO at $17 midpoint
Nuvalent, a preclinical oncology biotech developing small molecule kinase inhibitors, raised $166 million by offering 9.8 million shares at $17, within the range of $16 to $18. The company offered 0.9 million more shares than anticipated. Nuvalent focuses on...read more
Oncology biotech Nuvalent sets terms for $151 million IPO
Nuvalent, a preclinical oncology biotech developing small molecule kinase inhibitors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $151 million by offering 8.9 million shares at a price range of $16 to $18. At the...read more
US IPO Weekly Recap: Micro-caps lead a quiet 2 IPO week
After a record breaking number of deals last week, the IPO market cooled off for the shortened holiday week, with just two micro-cap IPOs raising $45 million. Preclinical RNA biotech Transcode Therapeutics (RNAZ) priced at $4 to...read more